PRTK - Paratek Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.24
+0.02 (+0.32%)
At close: 4:00PM EDT

6.24 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous close6.22
Open6.23
Bid6.23 x 800
Ask6.24 x 800
Day's range5.95 - 6.29
52-week range4.50 - 14.15
Volume208,742
Avg. volume364,325
Market cap202.276M
Beta (3Y monthly)1.97
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2014-10-31
1y target estN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Paratek Pharmaceuticals Announces Management Change

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that Douglas Pagán, Chief Financial Officer, has resigned, effective April 5, 2019, to join an early-stage biopharmaceutical company. Mr. Pagán has entered into a consulting agreement with Paratek through December 23, 2019 to assist the Company in the orderly transition of his Chief Financial Officer responsibilities. Paratek has initiated a search to identify and recruit a new candidate for the role of Chief Financial Officer.

  • GlobeNewswire19 days ago

    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on February 28, 2019, the Company granted stock options and restricted stock units to three new employees of the Company. The stock options are to acquire, in the aggregate, 9,750 shares of the Company’s common stock at a per share exercise price of $6.48, the closing sales price on February 28, 2019, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service.

  • GlobeNewswire20 days ago

    Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13 at 10:00 a.m. EDT at the Boston Marriott Copley Place in Boston. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/cowen52/prtk/.

  • GlobeNewswire21 days ago

    Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    -- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI -- -- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3.

  • GlobeNewswirelast month

    Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28 at 1:00 p.m. EST at the Lotte New York Palace in New York. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/leerink32/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.

  • GlobeNewswirelast month

    Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019

    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on February 27, 2019 at 4:30 p.m. EDT to report its fourth quarter and full year 2018 financial results and provide a corporate update. Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.

  • GlobeNewswirelast month

    New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections

    BOSTON, Feb. 06, 2019 -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies.

  • GlobeNewswirelast month

    Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States

    -- Three Antimicrobial Susceptibility Tests Cleared by FDA for Use with NUZYRA -- -- Launches  KEYSTONETM Surveillance Program to Monitor Omadacycline Susceptibility --.

  • GlobeNewswire4 months ago

    Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030

    BOSTON, Dec. 03, 2018 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire4 months ago

    Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced dosing of the first patient in a Phase 2 study evaluating the potential efficacy and safety of oral and intravenous (IV) omadacycline for the treatment of acute pyelonephritis, a common subset of complicated urinary tract infections (cUTI). “Urinary tract infection is one of the most commonly diagnosed bacterial infections and treating clinicians are limited by a lack of broad-spectrum, well-tolerated, once-daily oral antibiotics,” said Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek. “This important milestone signifies continued progress in the evaluation of the efficacy and safety of omadacycline, which has the potential to address this significant unmet need in this serious community-acquired infection.